skip to Main Content

International Deprexis Trial in Multiple Sclerosis (IDEMS) – a Multicenter Randomized Controlled Trial


Brief Summary:

This is an international, multicenter, randomized controlled trial of an internet-based CBT
intervention for depression (Deprexis) conducted in five MS centers in the US and Germany.
The trial consists of a three-arm primary trial phase and an extension phase targeted at


Inclusion criteria

– age > 18

– neurologist-confirmed diagnosis of MS (all forms)

– self-reported depressive symptoms (BDI-Fastscreen > 4)

– fluent in German or English (depending on study site),

– willingness to engage in self-administration of an iCBT intervention for 3 months and
complete follow-up

– ability to travel to the outpatient center for two clinical assessments (baseline and
month 3)

– internet access at home

Exclusion criteria:

– unwilling or unable to consent,

– diagnosis of bipolar or psychosis (as determined by M.I.N.I structured interview),

– substantial neurocognitive impairments such as dementia or autism

– moderate or high risk of suicide (according to MINI module C) or by clinical

– very severe depression that would interfere with the ability to participate in the
study (based on clinical judgment by the physician at the recruitment site).

– current psychotherapy/behavioral treatments for depression

– started pharmacotherapy for depression within the last 2 months

– MS relapse or steroid treatment in the last 4 weeks

– concurrent participation in another clinical trial that includes an intervention

– refusal to saving, processing and forwarding of pseudonymized data


  • Cedars-Sinai Medical Center, Los Angeles, California, United States, 90048
Back To Top